Chlorthalidone Monotherapy is the Most Appropriate Initial Pharmacotherapy
For this 65-year-old African American man with stage 1 hypertension (150/95 mm Hg) and no comorbidities, chlorthalidone monotherapy is the most appropriate initial pharmacotherapy in addition to lifestyle modifications.
Rationale Based on Guidelines
The 2017 ACC/AHA guidelines provide Class I, Level B-R recommendations specifically addressing this clinical scenario 1:
- In Black adults with hypertension but without heart failure or chronic kidney disease, initial antihypertensive treatment should include a thiazide-type diuretic or calcium channel blocker
- Thiazide-type diuretics are superior to RAS inhibitors (ACE inhibitors, ARBs) for preventing cardiovascular outcomes in Black patients
- Chlorthalidone specifically should be administered at 12.5-25 mg/day for optimal endpoint protection, as this dosing has proven efficacy in clinical outcome trials
Why Not Combination Therapy?
While the guidelines note that most Black patients with hypertension require ≥2 medications for BP control 1, combination therapy is most appropriate when BP is >15/10 mm Hg above target 2, 3. This patient's BP of 150/95 mm Hg is approximately 20/15 mm Hg above the <130/80 mm Hg target, which technically could justify combination therapy. However, the 2025 ACC/AHA guidelines clarify that monotherapy is reasonable for stage 1 hypertension (130-139/80-89 mm Hg) 4, and this patient's readings place him at the borderline between stage 1 and stage 2.
Why Chlorthalidone Over Other Options?
Chlorthalidone has superior evidence over other thiazides:
- More effective BP lowering than hydrochlorothiazide, particularly at night 5
- Longer therapeutic half-life
- More cardiovascular disease risk reduction data than hydrochlorothiazide 5
- In the ALLHAT trial, chlorthalidone was superior to lisinopril in preventing heart failure and stroke in Black patients 1, 6
Why not ACE inhibitors (ramipril, lisinopril, enalapril)?
- Less effective as monotherapy in Black patients for BP lowering 1, 6
- Less effective than thiazides and CCBs for preventing cardiovascular events in Black patients without CKD or heart failure 1
- Higher risk of angioedema in Black patients 1
- No compelling indication present (no CKD, heart failure, or diabetes with proteinuria)
Why not beta-blockers (metoprolol)?
- Not first-line therapy for uncomplicated hypertension
- Less effective than thiazides and CCBs for stroke prevention 1, 6
- Reserved for specific indications (post-MI, heart failure)
Why not dual RAS blockade (enalapril + losartan)?
- Explicitly contraindicated: simultaneous use of ACE inhibitor + ARB causes harm without additional benefit 4
Clinical Approach
Start with chlorthalidone 12.5-25 mg daily and reassess in 2-4 weeks 7. If BP remains uncontrolled after titration to maximum dose:
- Add a calcium channel blocker (amlodipine) as second agent
- Alternatively, add an ACE inhibitor or ARB if CCB not tolerated
- The combination of thiazide + CCB or thiazide + RAS blocker produces equivalent BP lowering in Black patients as in other populations 1
Important Caveats
- Monitor electrolytes (potassium, sodium) after initiating thiazide therapy
- Assess for volume depletion, particularly in elderly patients
- Reinforce lifestyle modifications (DASH diet, sodium restriction, weight management, physical activity) as these are particularly important in Black patients 1
- Target BP <130/80 mm Hg per current guidelines 1, 4
- If monotherapy fails to achieve target within 3 months, promptly add second agent rather than prolonging suboptimal control
Answer: E. Chlorthalidone